INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← Cardiology / Health Desk

Barley beta-glucan: three lipid measures, not one verdict

A randomized-trial review found lower LDL and non-HDL cholesterol without a significant apoB change.

Whole-food ingredients prepared without added oil

Illustrative food image, not a photograph of the study intervention.

A barley-specific question

This review asked whether diets enriched with barley beta-glucan changed three blood measurements: LDL cholesterol, non-HDL cholesterol and apolipoprotein B, or apoB. It included randomized controlled trials lasting at least three weeks, rather than studies that simply compared people who chose different breakfasts. Fourteen trials involving 615 participants entered the final analysis. The intervention was defined by barley beta-glucan enrichment, so the evidence should not be casually relabeled as a trial of all whole grains. Equally, the review did not test the linked barley recipe or establish that any particular home portion reproduces its interventions.

Ho HV, Sievenpiper JL, Zurbau A, Blanco Mejia S et al.. European journal of clinical nutrition, 2016. PMID 27273067 · DOI

The LDL result in its own units

The pooled LDL cholesterol difference was minus 0.25 mmol/l, with a 95% confidence interval from minus 0.30 to minus 0.20 mmol/l, compared with control diets. The median barley beta-glucan dose for this analysis was 6.5 grams daily, and the median trial duration was four weeks. These details describe the experiments, not a personal serving prescription. The result concerns a blood measurement over a relatively short period. It should not be rewritten as a percentage reduction in heart attacks or as a guarantee of the same LDL response in every person eating barley.

Ho HV, Sievenpiper JL, Zurbau A, Blanco Mejia S et al.. European journal of clinical nutrition, 2016. PMID 27273067 · DOI

Non-HDL and apoB did not tell identical stories

For non-HDL cholesterol, the pooled mean difference was minus 0.31 mmol/l, with a 95% confidence interval from minus 0.39 to minus 0.23 mmol/l. The median beta-glucan dose for that analysis was 6.9 grams daily, again over a median four weeks. The abstract reported no significant change in apoB. Keeping all three findings together is more informative than announcing that every lipid measure improved. It also prevents a selective account that highlights the favorable cholesterol results while leaving readers with the mistaken impression that the apoB analysis supported an equivalent change.

Ho HV, Sievenpiper JL, Zurbau A, Blanco Mejia S et al.. European journal of clinical nutrition, 2016. PMID 27273067 · DOI

A favorable average with substantial variation

The non-HDL analysis had considerable unexplained heterogeneity, quantified as an I-squared value of 98%. That is an important qualification to its favorable pooled average, not a detail to hide behind the confidence interval. The investigators used random-effects models and assessed trial quality and risk of bias, but the abstract still identifies unexplained variation between results. The defensible conclusion is therefore specific: these barley beta-glucan interventions lowered LDL and non-HDL cholesterol on average, while apoB did not change significantly. A barley dish is a culinary connection to that question, rather than a tested cardiovascular treatment.

Ho HV, Sievenpiper JL, Zurbau A, Blanco Mejia S et al.. European journal of clinical nutrition, 2016. PMID 27273067 · DOI